- Home
- VIVS vs MBIO Comparison
VIVS vs MBIO Comparison
Compare VIVS & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VIVS | MBIO |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | 13 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0M | 4.7M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | VIVS | MBIO |
|---|---|---|
| Price | $2.16 | $1.02 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.5M | 153.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $42.38 | N/A |
| Revenue Next Year | $15.42 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.42 | $0.53 |
| 52 Week High | $5.30 | $7.00 |
Technical Indicators
Market Signals| Indicator | VIVS | MBIO |
|---|---|---|
| Relative Strength Index (RSI) | 53.08 | 55.38 |
| Support Level | $2.08 | $1.00 |
| Resistance Level | $2.45 | $1.10 |
| Average True Range (ATR) | 0.18 | 0.08 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 74.51 | 87.93 |
Price Performance
Historical ComparisonAbout VIVS VivoSim Labs Inc.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.